Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC…

Overview of attention for article published in Head & Neck, July 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,657 followers.

RT @bradpalm1: Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of TVEC v GM-CSF https://t.co/7CI4xOGdmu $PVCT

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of TVEC v GM-CSF https://t.co/7CI4xOGdmu $PVCT

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.